Findings from the phase 2 ARCADIA trial suggest that treatment with a glucokinase activator may aid the recovery of people with diabetes who are hospitalized with severe COVID-19.

Study findings suggest that the presence of microvascular complications is associated with increased risk for all-cause mortality in people with type 2 diabetes hospitalized for COVID-19.

Two large cohort studies have demonstrated an increased likelihood of being diagnosed with type 2 diabetes in the months following SARS-CoV-2 infection.

Researchers confirm that higher glycated hemoglobin levels are associated with a higher risk for poor outcomes in people with type 2 diabetes and COVID-19, but the risk does not increase further beyond a certain threshold.

Findings from the COVAC-DM study suggest that people with type 1 or type 2 diabetes have an antibody response to COVID-19 vaccination that is similar to healthy individuals, with no association between glycemic control and antibody levels.

The proportion of on-target interstitial glucose values falls during the week following initial COVID-19 vaccination in people with type 1 diabetes, study findings indicate.

Response to vaccination against SARS-CoV-2 may be impaired in people with type 2 diabetes and poor glycemic control, but potentially improved if glucose levels are controlled, say researchers.

Stefan Bornstein provides an overview of the current understanding about COVID-19 and diabetes, including medications, vaccines, and the impact of SARS-CoV-2 infection on diabetic ketoacidosis.

The risk of severe COVID-19 in people with type 1 diabetes is confined to older people and those with diabetic complications, suggest UK audit data.

Research shows that COVID-19 mortality risk in people with type 2 diabetes varies only a little according to which antiglycemic medications they are taking at the time.

Elevated glucose levels and glycemic fluctuations during the first week of hospitalization for COVID-19 are associated with an increased risk for unfavorable outcomes, research suggests.

COVID-19 restrictions do not significantly impact glycated hemoglobin levels in individuals with type 2 diabetes, but those with poor psychologic wellbeing may experience worsening glycemic control, suggest findings from an Italian study.

The latest report from the CORONADO study reveals factors predictive of home discharge within 28 days among people with diabetes hospitalized with COVID-19, as well as those linked to mortality risk.

The risk for fatal or critical care unit-treated COVID-19 varies among people with diabetes and can be reasonably well predicted by their clinical history, UK study findings indicate.

Results from the CORONADO study indicate that use of DPP-4 inhibitors does not affect outcomes for people with type 2 diabetes admitted to hospital with COVID-19.

The humoral immune response to SARS-CoV-2 infection is similar in people with and without diabetes and is not influenced by hyperglycemia, research suggests.

An observational study suggests that prior metformin use may offer a protective effect against COVID-19 mortality in people with type 2 diabetes, but only for women.

Findings from a retrospective case–control study suggest that the DPP-4 inhibitor sitagliptin may improve outcomes in people with type 2 diabetes who are hospitalized with COVID-19.

A questionnaire study provides insights into the use and perception of telemedicine among people with type 1 diabetes during the COVID-19 pandemic.

Obesity is a significant predictor of poor COVID-19 outcomes in patients who also have type 2 diabetes, but only in those up to the age of 75 years, report French researchers.